{
  "docId": "019de073-ace7-72fb-abe1-daa413db1006",
  "docSlug": "7bdf7da39a85a072a380631ad1d0379d",
  "documentTitle": "Cabaletta Bio | Investor Presentation Deck | 23 slides",
  "authorId": "cabaletta-bio",
  "authorName": "Cabaletta Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 23,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide uses a table format to present a roadmap of clinical milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-ace7-72fb-abe1-daa413db1006/22",
  "deckHref": "/decks/019de073-ace7-72fb-abe1-daa413db1006",
  "deckJsonHref": "/decks/019de073-ace7-72fb-abe1-daa413db1006.json",
  "deckAnchorHref": "/decks/019de073-ace7-72fb-abe1-daa413db1006#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.1,
        "y": 0.75
      },
      "kind": "callout",
      "text": "Cash runway extended through 2Q 2024 with $96.8M at the end of 2Q 2022",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1870344-9c63-4c20-b5b8-7b0f0d714cf3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1. Assumes no dose-limiting toxicities... 2. Pending clearance of CABA-201 IND by the FDA.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b4f9b9d-27f0-42a6-a793-6cc7a497b9b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.8,
        "x": 0.1,
        "y": 0.2
      },
      "kind": "table",
      "text": "CABA-201, DSG3-CAART, MuSK-CAART milestones and timing",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a6959814-2c16-4cbf-899a-71a5d110a76f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Multiple potential clinical catalysts anticipated in next 12-18 months",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e657c754-ff69-432c-a256-e8d8a146e813",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "3358fab3-9f12-40f8-9da1-c2d4aac6638e",
      "evidence": "The slide presents a timeline of milestones for multiple projects.",
      "confidence": 0.7
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}